Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ
Lancet Oncol. 2018 Dec;19(12):1579-1589
CARDIONCOLOGY.ORG ABSTRACT:
This study identifies and characterizes cardiovascular fatal immune-related adverse- events (irAEs) associated with immune checkpoint inhibitors (ICIs).
Results indicate that treatment with ICIs can lead to severe and disabling inflammatory cardiovascular irAEs soon after commencement of therapy.
© All Rights Reserved
Image source: https://www.farcomtrento.com/farmacovigilanza/